Oncology

Sintilimab Plus Bevacizumab Biosimilar Therapy Associated With Better Outcomes, Higher Costs Than Lenvatinib

February 25th 2023

By Deana Ferreri, PhD

According to the authors of a cost-effectiveness analysis of treatments for hepatocellular carcinoma (HCC) in China, sintilimab plus a bevacizumab biosimilar could improve quality of life for patients, but at a higher cost than lenvatinib.

Biosimilar Business Recap: New Ustekinumab Partnership; Similis Bio Biosimilar Programs; Celltrion Japan Launch

February 23rd 2023

By Skylar Jeremias

Article

Fresenius Kabi announced a global partnership with Formycon for an ustekinumab biosimilar; Similis Bio partners with Novel351K to co-develop 3 biosimilars; and Celltrion Healthcare launched its bevacizumab biosimilar in Japan.

Fresenius Kabi Launches Stimufend in the US

February 16th 2023

By Skylar Jeremias

Article

Fresenius Kabi announced the US launch of its pegfilgrastim biosimilar Stimufend (pegfilgrastim-fpgk), making it the fifth biosimilar referencing Neulasta to enter the market.

FDA Issues CRL for Biocon Biologics, Viatris Avastin Biosimilar

February 14th 2023

By Skylar Jeremias

Article

Biocon Biologics and its partner Viatris received a complete response letter (CRL) for their biosimilar referencing Avastin (bevacizumab), the second CRL for the companies in 2023. The news comes as Biocon publishes increased revenues for biosimilars and generics.

Eye on Pharma: Formycon Aflibercept Data; Sandoz CHMP Nod; Henlius Daratumumab Study

February 8th 2023

By Skylar Jeremias

Article

Formycon shared positive data on its Eylea (aflibercept) biosimilar; Sandoz received a thumbs up from the European Union’s Committee for Medicinal Products for Human Use (CHMP); and Shanghai Henlius Biotech began a phase 1 study for its daratumumab biosimilar candidate.

Biosimilars Check-in: Approval in Saudi Arabia, Launch in Republic of Korea, Dr. Reddy’s Completes Study

January 26th 2023

By Skylar Jeremias

Article

Saudi Arabia approved an adalimumab biosimilar, a denosumab biosimilar entered the market in the Republic of Korea, and Dr. Reddy’s Laboratories announced the completion of a phase 3 study for its rituximab biosimilar.

Global Use of Medicines Report Predicts Biosimilars Will Save $290 Billion by 2027

January 25th 2023

By Skylar Jeremias

Article

IQVIA’s Global Use of Medicines Report for 2023 has revealed increased uptake of biosimilars around the world and predicted that biosimilars could generate nearly $300 billion in savings by 2027.

Phase 3 Study Finds Bioequivalence Between Celltrion Bevacizumab Biosimilar, Avastin for NSCLC

January 21st 2023

By Skylar Jeremias

Article

Celltrion Healthcare’s candidate bevacizumab biosimilar CT-P16 demonstrated equivalent efficacy, safety, and immunogenicity to Avastin (reference bevacizumab), in a phase 3 clinical trial in patients with non–small cell lung cancer (NSCLC).

Canada Approves Celltrion Bevacizumab Biosimilar

January 17th 2023

By Skylar Jeremias

Article

Health Canada has granted approval for Celltrion Healthcare’s bevacizumab biosimilar (Vegzelma) referencing Avastin for the treatment of multiple forms of cancer.

The Top 5 Oncology Articles of 2022

December 26th 2022

By Skylar Jeremias

Article

The top 5 most-read articles about oncology within the biosimilars industry involved a number of FDA approvals and new data on the market impact of biosimilar competition on Roche’s blockbuster reference products.